Shares of Amgen Inc. AMGN slipped 1.37% to $272.05 Thursday, on what proved to be an all-around positive trading session for ...

Some research has shown that dividend-paying stocks significantly outperformed their non-dividend-paying peers over the past ...

Amgen's diverse portfolio ensures stability, but risks like high debt and biosimilar competition loom. Check out my look at ...

It’s been 19 months since Amgen completed its $27.8 billion acquisition of Horizon Therapeutics, and the California company ...

Amgen on Thursday said its first-quarter profit rose 24%, driven by product sales, and said that while it is premature to ...

Amgen on Thursday said its first-quarter profit rose 24%, handily exceeding Wall Street expectations, as product sales ...

The U.K. drug regulator on Wednesday approved Amgen’s (NASDAQ:AMGN) intravenous medication teprotumumab (Tepezza) as the ...

Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options ...

The stable outlook reflects S&P Global Ratings’ expectation that Amgen’s revenue and EBITDA will remain stable despite patent ...

Sales of the company’s copycat to J&J’s blockbuster medicine reached $150 million in the first quarter, adding to a surge in ...

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Amgen has announced a significant expansion of the Ohio manufacturing facility in the US, with an investment of $900m.